Information contained on this page is provided by companies via press release distributed through PR Newswire, an independent third-party content provider. PR Newswire, WorldNow and this Station make no warranties or representations in connection therewith.
SOURCE Syneron Beauty Inc.
The first and only at-home hair removal system FDA cleared to be safe and effective for all skin tones
NEW YORK, Feb. 27, 2013 /PRNewswire/ -- Syneron Beauty Inc., a subsidiary of Syneron Medical Ltd. (NASDAQ: ELOS), the leading global aesthetic device company, announces the launch of the me smooth (www.mePower.com), a revolutionary at-home professional hair removal device for all skin tones using Syneron's patented elos technology.
SAFE AND EFFECTIVE FOR ALL SKIN TONES
The me smooth is the only consumer hair removal solution that is FDA cleared and clinically proven to be safe and effective on all skin types and tones. Powered by elos (electro-optical synergy) technology, combining the power of Intense Pulsed Light (IPL) and Radio Frequency (RF) energies, me smooth selectively targets the hair follicles and delivers heat deep into the dermis to inhibit hair regrowth. The result? Hair removal with unprecedented speed, ease and effectiveness, all in the privacy of your own home. With me smooth, consumers with all skin tones can now achieve smooth, stubble-free skin without the limitations and hassle of older hair removal solutions.
"We are excited to be launching the me brand in the U.S., and our inaugural product, the me smooth, represents a breakthrough in professional at-home hair removal," states Fabian Tenenbaum, Chief Executive Officer of Syneron Beauty. "With me smooth, we have made our patented elos technology available to consumers, providing the first at-home hair removal device that is FDA cleared to be used on all skin types."
CLINICALLY PROVEN TECHNOLOGY
Before bringing me smooth to U.S. consumers, Syneron Beauty gained FDA-clearance after conducting extensive safety, efficacy and usage studies. The company held clinical studies with over 100 patients at five leading U.S. dermatologist's sites. Patients enrolled in the study represented diverse racial backgrounds and covered all Fitzpatrick skin types. "Using me smooth for hair removal was confirmed to be safe for the full range of skin tones as well as effective for body hair reduction," notes Jerome M. Garden, MD, of the Department of Dermatology at Northwestern Memorial Hospital, Chicago, IL.
Clinical studies indicate the strong efficacy of me smooth. In trials, quantifiable hair clearance was found in all skin type groups, including skin types V and VI. In a clinical study, the me smooth was used for only 7 weekly treatments and achieved up to 96 percent hair reduction three months after the last treatment.
me smooth uses patented elos technology which was created by the co-founder of Syneron Medical Ltd., Dr. Shimon Eckhouse, who also invented IPL – the previous generation of hair removal and a wide range of skin treatment technologies. elos is already widely used by plastic surgeons and dermatologists, with over three million elos treatments performed annually by professionals around the world. Now the benefits of this breakthrough technology are available to consumers to use in the comfort and privacy of their own home.
FAST, EASY, AND GENTLE
me smooth is also fast, simple, painless and intuitive to use. You can now treat full legs in as little as 10 minutes. Simply glide the me over the skin and let the flashing elos energy take care of the rest. The treatment is painless, and eliminates the burning, snapping, nicks, cuts and irritation often associated with other hair removal solutions.
me smooth retails for $395 and is pre-loaded with 6,000 pulses. The elos replacement cartridge will retail for $50.
me smooth will be on-shelf in May 2013 at prestige beauty retailers including Nordstrom, Neiman Marcus, Bloomingdales, Ulta, Sephora and Space NK as well as on QVC and mePower.com.
ABOUT SYNERON BEAUTY
Syneron Beauty is a pioneer in the design, development and distribution of energy-based consumer aesthetic products. The Company's products are based on clinically proven technologies derived from the professional medical aesthetic device market, enabling patients to achieve professional-like results in an at-home setting. Syneron Beauty currently markets the me™ brand of home-use hair removal systems, the Pearl™ family of teeth whitening products and the Tanda™ family of home-use light therapy products. Syneron Beauty is based in New York and is a wholly owned subsidiary of Syneron Medical Ltd. (NASDAQ: ELOS).
ABOUT SYNERON MEDICAL LTD.
Syneron Medical Ltd. (NASDAQ: ELOS) is the leading global aesthetic device company with a comprehensive product portfolio and a global distribution footprint. The Company's technology enables physicians to provide advanced solutions for a broad range of medical-aesthetic applications including body contouring, hair removal, wrinkle reduction, rejuvenation of the skin's appearance through the treatment of superficial benign vascular and pigmented lesions, and the treatment of acne, leg veins and cellulite. The Company sells its products under two distinct brands, Syneron and Candela. Founded in 2000, the corporate, R&D, and manufacturing headquarters for Syneron Medical Ltd. are located in Israel. Syneron also has R&D and manufacturing operations in the US. The Company markets, services and supports its products in 90 countries. It has offices in North America, France, Germany, Italy, Portugal, Spain, UK, Australia, China, Japan, and Hong Kong and distributors worldwide.
SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS
Any statements contained in this document regarding future expectations, beliefs, goals, plans or prospects constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Further, any statements that are not statements of historical fact (including statements containing "believes," "are confident that, "anticipates," "plans," "expects," "may," "will," "would," and similar expressions) should also be considered to be forward-looking statements. There are a number of factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including the risk that the product launch may take longer than expected, as well as the risks set forth in Syneron Medical Ltd.'s most recent Annual Report on Form 20-F, and the other factors described in the filings that Syneron Medical Ltd. makes with the SEC from time to time. If one or more of these factors materialize, or if any underlying assumptions prove incorrect, Syneron Medical Ltd.'s actual results, performance or achievements may vary materially from any future results, performance or achievements expressed or implied by these forward-looking statements.
In addition, the statements in this document reflect the expectations and beliefs of Syneron Medical Ltd. as of the date of this document. Syneron Medical Ltd. anticipates that subsequent events and developments will cause its expectations and beliefs to change. However, while Syneron Medical Ltd. may elect to update these forward-looking statements publicly in the future, it specifically disclaims any obligation to do so. The forward-looking statements of Syneron Medical Ltd. do not reflect the potential impact of any future dispositions or strategic transactions that may be undertaken. These forward-looking statements should not be relied upon as representing Syneron Medical Ltd.'s views as of any date after the date of this document.
©2012 PR Newswire. All Rights Reserved.